The Biochemical, Biological, and Pathological Kaleidoscope of Cell Surface Substrates Processed by Matrix Metalloproteinases
暂无分享,去创建一个
B. Cauwe | P. E. Van den Steen | G. Opdenakker | Ghislain Opdenakker | Bénédicte Cauwe | Philippe E. Van den Steen | Bénédicte Cauwe
[1] Yi Tang,et al. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. , 2004, Molecular cancer research : MCR.
[2] R. Hammer,et al. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation , 1992, Cell.
[3] J. Arribas,et al. The Shedding of Betaglycan Is Regulated by Pervanadate and Mediated by Membrane Type Matrix Metalloprotease-1* , 2004, Journal of Biological Chemistry.
[4] T. Luger,et al. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. , 2006, Cancer research.
[5] Hiroshi Sato,et al. Roles of membrane‐type matrix metalloproteinase‐1 in tumor invasion and metastasis , 2005, Cancer science.
[6] G. Opdenakker,et al. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. , 1993, Biochemical and biophysical research communications.
[7] 岡田 伸太郎,et al. Matrix Metalloproteinase-9 , 1998, Definitions.
[8] S. Ménard,et al. Formation of the 67‐kDa laminin receptor by acylation of the precursor , 1998, Journal of cellular biochemistry.
[9] A. Gearing,et al. Design and therapeutic application of matrix metalloproteinase inhibitors. , 1999, Chemical reviews.
[10] L. Liotta,et al. Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. , 1994, Biochemistry.
[11] Li Yan,et al. Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression , 2005, Thrombosis and Haemostasis.
[12] Alex Y Strongin,et al. An Alternative Processing of Integrin αv Subunit in Tumor Cells by Membrane Type-1 Matrix Metalloproteinase* , 2002, The Journal of Biological Chemistry.
[13] L. Blavier,et al. Considering the critical interface between tumor cells and stromal cells in the search for targets for anticancer therapy. , 2005, Cancer cell.
[14] D. Green,et al. Metalloproteinase shedding of Fas ligand regulates beta-amyloid neurotoxicity. , 2002, Current biology : CB.
[15] E. Mekada,et al. Heparin-binding EGF-like growth factor: a juxtacrine growth factor. , 2000, Cytokine & growth factor reviews.
[16] B. Fingleton,et al. Matrilysin (matrix metalloproteinase-7) selects for apoptosis-resistant mammary cells in vivo. , 2002, Cancer research.
[17] P. Altevogt,et al. Metalloproteinase-mediated release of the ectodomain of L1 adhesion molecule. , 1999, Journal of cell science.
[18] M. Umeda,et al. GelatinaseA and APP , 1994, Nature.
[19] C. S. St. Hill,et al. ADAM‐17‐independent shedding of L‐selectin , 2003, Journal of leukocyte biology.
[20] A. Strongin,et al. Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. , 2002, The Journal of biological chemistry.
[21] B. Fingleton,et al. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. , 2000, The Journal of clinical investigation.
[22] M. Torrisi,et al. Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[23] Gillian Murphy,et al. Structure and function of matrix metalloproteinases and TIMPs. , 2006, Cardiovascular research.
[24] T. Isobe,et al. Membrane Type 1 Matrix Metalloproteinase (MT1-MMP/MMP-14) Cleaves and Releases a 22-kDa Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Fragment from Tumor Cells* , 2006, Journal of Biological Chemistry.
[25] Y. Dai,et al. Characterization of the soluble form of the low density lipoprotein receptor-related protein (LRP). , 1999, Experimental cell research.
[26] C. Blobel,et al. Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding. , 2003, The Journal of biological chemistry.
[27] Y. Yarden,et al. Oncogenic growth factor receptors: implications for signal transduction therapy. , 2004, Seminars in cancer biology.
[28] I. Nishino,et al. Proteolysis of β-dystroglycan in muscular diseases , 2005, Neuromuscular Disorders.
[29] William C. Parks,et al. Matrilysin Shedding of Syndecan-1 Regulates Chemokine Mobilization and Transepithelial Efflux of Neutrophils in Acute Lung Injury , 2002, Cell.
[30] H. Saya,et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway , 2001, The Journal of cell biology.
[31] P. Altevogt,et al. Cleavage of L1 in Exosomes and Apoptotic Membrane Vesicles Released from Ovarian Carcinoma Cells , 2005, Clinical Cancer Research.
[32] G. Davis,et al. Ischemia-induced cleavage of cadherins in NRK cells: evidence for a role of metalloproteinases. , 2005, American journal of physiology. Renal physiology.
[33] S. Belmadani,et al. Involvement of Metalloproteinases 2/9 in Epidermal Growth Factor Receptor Transactivation in Pressure-Induced Myogenic Tone in Mouse Mesenteric Resistance Arteries , 2004, Circulation.
[34] R. Caldwell,et al. TGF-beta increases retinal endothelial cell permeability by increasing MMP-9: possible role of glial cells in endothelial barrier function. , 2001, Investigative ophthalmology & visual science.
[35] A. Steinle,et al. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. , 2006, Cancer research.
[36] D. Gomez,et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. , 1997, European journal of cell biology.
[37] B. C. Patterson,et al. Angiostatin-converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9)* , 1997, The Journal of Biological Chemistry.
[38] E. Milgrom,et al. Shedding of Human Thyrotropin Receptor Ectodomain , 1996, The Journal of Biological Chemistry.
[39] E. Bröcker,et al. Granulocyte‐derived elastase and gelatinase B are required for dermal–epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid , 2004, The Journal of pathology.
[40] Hiroshi Ohno,et al. Cytoplasmic tail–dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity , 2001, The Journal of cell biology.
[41] William C. Parks,et al. Matrix metalloproteinases as modulators of inflammation and innate immunity , 2004, Nature Reviews Immunology.
[42] K. Brew,et al. Tissue inhibitors of metalloproteinases: evolution, structure and function. , 2000, Biochimica et biophysica acta.
[43] G. Opdenakker,et al. Cytokine-regulated proteases in autoimmune diseases. , 1994, Immunology today.
[44] M. Feldmann,et al. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. , 1996, The Journal of clinical investigation.
[45] I. Mikhailenko,et al. Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability , 2005, Journal of thrombosis and haemostasis : JTH.
[46] A. Hopkins,et al. ICAM-1: targeted docking for exogenous as well as endogenous ligands. , 2004, Advanced drug delivery reviews.
[47] N. Mitsiades,et al. The role of Fas and FasL as mediators of anticancer chemotherapy. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[48] N. Hooper,et al. Membrane protein secretases. , 1997, The Biochemical journal.
[49] D. Rifkin,et al. Cellular glycosylphosphatidylinositol‐specific phospholipase D regulates urokinase receptor shedding and cell surface expression , 1999, Journal of cellular physiology.
[50] Motoharu Seiki,et al. MT1‐MMP: A potent modifier of pericellular microenvironment , 2006, Journal of cellular physiology.
[51] S. Itohara,et al. Unaltered Secretion of β-Amyloid Precursor Protein in Gelatinase A (Matrix Metalloproteinase 2)-deficient Mice* , 1997, The Journal of Biological Chemistry.
[52] A. Kozik,et al. Effect of oxidation of β‐amyloid precursor protein on its β‐secretase cleavage. A model study with synthetic peptides and candidate β‐secretases , 2009 .
[53] D. Green,et al. Metalloproteinase Shedding of Fas Ligand Regulates β-Amyloid Neurotoxicity , 2002, Current Biology.
[54] T. Yoshizaki,et al. Cleavage of Syndecan-1 by Membrane Type Matrix Metalloproteinase-1 Stimulates Cell Migration* , 2003, Journal of Biological Chemistry.
[55] R. Dwek,et al. The Hemopexin and O-Glycosylated Domains Tune Gelatinase B/MMP-9 Bioavailability via Inhibition and Binding to Cargo Receptors* , 2006, Journal of Biological Chemistry.
[56] H. Mori,et al. Membrane-Type 1 Matrix Metalloproteinase Cleaves Cd44 and Promotes Cell Migration , 2001, The Journal of cell biology.
[57] Gillian Murphy,et al. Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface , 2003, Journal of Cell Science.
[58] W. Birchmeier,et al. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. , 1994, Biochimica et biophysica acta.
[59] D. Górecki,et al. Aberrant expression, processing and degradation of dystroglycan in squamous cell carcinomas. , 2004, European journal of cancer.
[60] C. Blobel,et al. Tumor Necrosis Factor-α Converting Enzyme/ADAM 17 Mediates MUC1 Shedding* , 2003, The Journal of Biological Chemistry.
[61] M. Greenberg,et al. β-Amyloid Induces Neuronal Apoptosis Via a Mechanism that Involves the c-Jun N-Terminal Kinase Pathway and the Induction of Fas Ligand , 2001, The Journal of Neuroscience.
[62] L. Kotra,et al. Complex Pattern of Membrane Type 1 Matrix Metalloproteinase Shedding , 2002, The Journal of Biological Chemistry.
[63] G. Murphy,et al. Metalloproteinase-mediated Regulation of L-selectin Levels on Leucocytes (*) , 1996, The Journal of Biological Chemistry.
[64] Yunbo Shi,et al. The matrix metalloproteinase stromelysin-3 cleaves laminin receptor at two distinct sites between the transmembrane domain and laminin binding sequence within the extracellular domain , 2005, Cell Research.
[65] A. Reichenbach,et al. Role of Muller cells in retinal degenerations. , 2001, Frontiers in bioscience : a journal and virtual library.
[66] Carlos Fernandez-Patron,et al. Agonist-Induced Activation of Matrix Metalloproteinase-7 Promotes Vasoconstriction Through the Epidermal Growth Factor–Receptor Pathway , 2004, Circulation research.
[67] B. Fingleton,et al. Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.
[68] M. Cullen,et al. Matrix Metalloproteinases in Dog Brains Exhibiting Alzheimer‐Like Characteristics , 1997, Journal of neurochemistry.
[69] Z. Werb,et al. Matrix Metalloproteinase Stromelysin-1 Triggers a Cascade of Molecular Alterations That Leads to Stable Epithelial-to-Mesenchymal Conversion and a Premalignant Phenotype in Mammary Epithelial Cells , 1997, The Journal of cell biology.
[70] H. Matsuno,et al. Potential withdrawal of rheumatoid synovium by the induction of apoptosis using a novel in vivo model of rheumatoid arthritis. , 1998, Arthritis and rheumatism.
[71] L. Taubner,et al. Tumor shedding of laminin binding protein modulates angiostatin production in vitro and interferes with plasmin‐derived inhibition of angiogenesis in aortic ring cultures , 2006, International journal of cancer.
[72] W. Sakr,et al. Cleavage at the stem region releases an active ectodomain of the membrane type 1 matrix metalloproteinase. , 2005, The Biochemical journal.
[73] W. Parks,et al. Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. , 2003, The American journal of pathology.
[74] Jeffrey W. Smith,et al. Functional activation of integrin αvβ3 in tumor cells expressing membrane‐type 1 matrix metalloproteinase , 2000 .
[75] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[76] I. Weissman,et al. A cell-surface molecule involved in organ-specific homing of lymphocytes , 1983, Nature.
[77] A. Ullrich,et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF , 1999, Nature.
[78] A. H. Drummond,et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. , 1994, Nature.
[79] J. Foidart,et al. Upregulation of MMPs by soluble E‐cadherin in human lung tumor cells , 2003, International journal of cancer.
[80] S. Moe,et al. Opposing Effects of Transmembrane and Soluble FAS Ligand Expression on Inflammation and Tumor Cell Survival , 2000, The Journal of experimental medicine.
[81] K. Guan,et al. Class IV Semaphorins Promote Angiogenesis by Stimulating Rho-Initiated Pathways through Plexin-B , 2004, Cancer Research.
[82] Y. Itoh,et al. MT1-MMP: an enzyme with multidimensional regulation. , 2004, Trends in biochemical sciences.
[83] E. Sturrock,et al. Soluble LDL-R are formed by cell surface cleavage in response to phorbol esters. , 2004, European journal of biochemistry.
[84] M. Ball,et al. Proteolysis of Aβ Peptide from Alzheimer Disease Brain by Gelatinase A , 1994 .
[85] Michael A. Hollingsworth,et al. Mucins in cancer: protection and control of the cell surface , 2004, Nature Reviews Cancer.
[86] J. Marvaldi,et al. Role of Endoproteolytic Processing in the Adhesive and Signaling Functions of αvβ5 Integrin* , 2000, The Journal of Biological Chemistry.
[87] S. Gordon,et al. A Functional Soluble Form of the Murine Mannose Receptor Is Produced by Macrophages in Vitro and Is Present in Mouse Serum* , 1998, The Journal of Biological Chemistry.
[88] Brian Chung,et al. Linking Receptor-mediated Endocytosis and Cell Signaling , 2004, Journal of Biological Chemistry.
[89] G. Murphy,et al. Tissue Inhibitor of Metalloproteinases-3 Inhibits Shedding of L-selectin from Leukocytes* , 1999, The Journal of Biological Chemistry.
[90] M. Gerhart,et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing , 1994, Nature.
[91] M. Lisanti,et al. Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. , 1996, The Journal of biological chemistry.
[92] J. Woessner,et al. Heparan Sulfate Proteoglycans as Extracellular Docking Molecules for Matrilysin (Matrix Metalloproteinase 7)* , 2000, The Journal of Biological Chemistry.
[93] I. Stamenkovic,et al. Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. , 2000, The American journal of pathology.
[94] S. Ménard,et al. Peptide G, Containing the Binding Site of the 67-kDa Laminin Receptor, Increases and Stabilizes Laminin Binding to Cancer Cells* , 1996, The Journal of Biological Chemistry.
[95] M. Ploug,et al. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. , 1994, FEBS letters.
[96] A. Strongin,et al. Matrix-dependent Proteolysis of Surface Transglutaminase by Membrane-type Metalloproteinase Regulates Cancer Cell Adhesion and Locomotion* , 2001, The Journal of Biological Chemistry.
[97] C. López-Otín,et al. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. , 2004, The International journal of developmental biology.
[98] H. Rammensee,et al. Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding , 2002, The Journal of Immunology.
[99] R. Fridman,et al. Processing, shedding, and endocytosis of membrane type 1‐matrix metalloproteinase (MT1‐MMP) , 2004, Journal of cellular physiology.
[100] J. Tonn,et al. Production of MMPs in Human Cerebral Endothelial Cells and Their Role in Shedding Adhesion Molecules , 2001, Journal of neuropathology and experimental neurology.
[101] B. Toole,et al. Hyaluronan: from extracellular glue to pericellular cue , 2004, Nature Reviews Cancer.
[102] R. Burghardt,et al. Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14). , 2006, American journal of physiology. Renal physiology.
[103] D. Hadjipavlou-Litina,et al. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results. , 2005, Current medicinal chemistry.
[104] T. Sano,et al. [Diabetic retinopathy]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.
[105] M. Furman,et al. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. , 2004, Journal of the American College of Cardiology.
[106] Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-alphav integrin regulates cross-talk between alphavbeta3 and alpha2beta1 integrins in breast carcinoma cells. , 2003, Experimental cell research.
[107] Ronit Vogt Sionov,et al. CD44: structure, function, and association with the malignant process. , 1997, Advances in cancer research.
[108] C. Masters,et al. Degradation of the Alzheimer Disease Amyloid β-Peptide by Metal-dependent Up-regulation of Metalloprotease Activity* , 2006, Journal of Biological Chemistry.
[109] Nicole Nelson,et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.
[110] S. Chandler,et al. Matrix metalloproteinases degrade myelin basic protein , 1995, Neuroscience Letters.
[111] C. Powers,et al. Fibroblast growth factors, their receptors and signaling. , 2000, Endocrine-related cancer.
[112] M. Fini,et al. Effects of Matrix Metalloproteinase-9 Gene Knock-Out on the Proteolysis of Blood–Brain Barrier and White Matter Components after Cerebral Ischemia , 2001, The Journal of Neuroscience.
[113] M. Ploug,et al. Structure—function relationships in the receptor for urokinase‐type plasminogen activator Comparison to other members of the Ly‐6 family and snake venom α‐neurotoxins , 1994 .
[114] R. Sciot,et al. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. , 1999, The Journal of clinical investigation.
[115] R. Dwek,et al. Matrix remodelling enzymes, the protease cascade and glycosylation. , 2001, Biochimica et biophysica acta.
[116] N. Bunnett,et al. Protease-activated receptors: contribution to physiology and disease. , 2004, Physiological reviews.
[117] A. Bensussan,et al. A Soluble Form of the MHC Class I-Specific CD160 Receptor Is Released from Human Activated NK Lymphocytes and Inhibits Cell-Mediated Cytotoxicity1 , 2007, The Journal of Immunology.
[118] B. Fingleton,et al. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis , 1999, Current Biology.
[119] P. Dempsey,et al. Tyrosine Phosphorylation and Proteolysis , 1998, The Journal of Biological Chemistry.
[120] D. Carey,et al. Matrix metalloproteinase‐dependent shedding of syndecan‐3, a transmembrane heparan sulfate proteoglycan, in Schwann cells , 2003, Journal of neuroscience research.
[121] J. Mitchison. Cell Biology , 1964, Nature.
[122] Z. Werb,et al. New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.
[123] S. Roman-Roman,et al. Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16) , 1998, European journal of immunology.
[124] R. Coffey,et al. Cell Surface Ectodomain Cleavage of Human Amphiregulin Precursor Is Sensitive to a Metalloprotease Inhibitor , 1998, The Journal of Biological Chemistry.
[125] X. Puente,et al. Membrane Type 4 Matrix Metalloproteinase (MMP17) Has Tumor Necrosis Factor-α Convertase Activity but Does Not Activate Pro-MMP2* , 2000, The Journal of Biological Chemistry.
[126] R. Caldwell,et al. TGF-β increases retinal endothelial cell permeability by increasing MMP-9 : Possible role of glial cells in endothelial barrier function , 2001 .
[127] S. Rafii,et al. Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.
[128] A. Churg,et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release. , 2003, American journal of respiratory and critical care medicine.
[129] Alex Y Strongin,et al. Cell-surface-associated tissue transglutaminase is a target of MMP-2 proteolysis. , 2004, Biochemistry.
[130] A. Ullrich,et al. The EGF receptor as central transducer of heterologous signalling systems. , 1999, Trends in pharmacological sciences.
[131] P. Thompson,et al. Modulatory effects of sCD14 and LBP on LPS-host cell interactions , 2005, Journal of endotoxin research.
[132] M. Hirashima,et al. Regulation of galectin-9 expression and release in Jurkat T cell line cells. , 2002, Glycobiology.
[133] S. Coughlin,et al. Thrombin signalling and protease-activated receptors , 2000, Nature.
[134] D. Sheppard,et al. Heparin-binding epidermal growth factor cleavage mediates zinc-induced epidermal growth factor receptor phosphorylation. , 2004, American journal of respiratory cell and molecular biology.
[135] A. Strongin,et al. Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. , 2000, International journal of cancer.
[136] P. Ongusaha,et al. HB-EGF Is a Potent Inducer of Tumor Growth and Angiogenesis , 2004, Cancer Research.
[137] D. Gingras,et al. Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains. , 2001, The Biochemical journal.
[138] M. Seiki,et al. Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors , 2003, Oncogene.
[139] T. van der Poll,et al. The Metalloproteinase Inhibitor GI5402 Inhibits Endotoxin-Induced Soluble CD27 and CD16 Release in Healthy Humans , 2000, Infection and Immunity.
[140] R. Coffey,et al. Apical Enrichment of Human EGF Precursor in Madin-Darby Canine Kidney Cells Involves Preferential Basolateral Ectodomain Cleavage Sensitive to a Metalloprotease Inhibitor , 1997, The Journal of cell biology.
[141] M. Oda,et al. Analysis of the ternary complex formation of human urokinase with the separated two domains of its receptor. , 1998, European journal of biochemistry.
[142] L. Matrisian,et al. Matrix metalloproteinases: they're not just for matrix anymore! , 2001, Current opinion in cell biology.
[143] L. Pegg,et al. ADAMTS-4 (aggrecanase-1): N-terminal activation mechanisms. , 2005, Archives of biochemistry and biophysics.
[144] Marcel Mettlen,et al. Regulation of matrix metalloproteinase (MMP) activity by the low-density lipoprotein receptor-related protein (LRP). A new function for an "old friend". , 2005, Biochimie.
[145] R. Elble,et al. The Breast Cancer β4 Integrin and Endothelial Human CLCA2 Mediate Lung Metastasis* , 2001, The Journal of Biological Chemistry.
[146] C. Overall,et al. Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1* , 2001, The Journal of Biological Chemistry.
[147] R. Black,et al. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. , 1995, Journal of immunology.
[148] K. Miyazaki,et al. Novel processing of beta-amyloid precursor protein catalyzed by membrane type 1 matrix metalloproteinase releases a fragment lacking the inhibitor domain against gelatinase A. , 2003, Biochemistry.
[149] M. De Ley,et al. Homogeneous interferon-inducing 22K factor is related to endogenous pyrogen and interleukin-1 , 1985, Nature.
[150] Gillian Murphy,et al. Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.
[151] R. Mayer,et al. Hydroxamate-based inhibitors of low affinity IgE receptor (CD23) processing. , 1998, Bioorganic & medicinal chemistry letters.
[152] G. Opdenakker,et al. Matrix Metalloproteinase-9 Facilitates Remyelination in Part by Processing the Inhibitory NG2 Proteoglycan , 2003, The Journal of Neuroscience.
[153] D. Strickland,et al. Diverse roles for the LDL receptor family , 2002, Trends in Endocrinology & Metabolism.
[154] Hiroyuki Arai,et al. Matrix metalloproteinase (MMP) system in brain: identification and characterization of brain‐specific MMP highly expressed in cerebellum , 2001, The European journal of neuroscience.
[155] S. Roman-Roman,et al. A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. , 1997, Cytokine.
[156] K. Miyazaki,et al. Identification of a Region of β-Amyloid Precursor Protein Essential for Its Gelatinase A Inhibitory Activity* , 2003, The Journal of Biological Chemistry.
[157] A. Kahn,et al. The Cell Surface , 1974, Advances in Experimental Medicine and Biology.
[158] M. Rouis. Matrix metalloproteinases: a potential therapeutic target in atherosclerosis. , 2005, Current drug targets. Cardiovascular & haematological disorders.
[159] J. Gutkind,et al. Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[160] H. Birkedal‐Hansen,et al. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[161] T. Sumida,et al. Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer , 1998, Gene Therapy.
[162] Y. Ma,et al. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[163] O. Huber,et al. Cleavage and Shedding of E-cadherin after Induction of Apoptosis* , 2001, The Journal of Biological Chemistry.
[164] J. Baselga,et al. Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme. , 2001, The Journal of biological chemistry.
[165] R. Kemler,et al. Control over Wnt target gene expression , 2000 .
[166] K. Irie,et al. Ectodomain shedding of nectin-1alpha by SF/HGF and TPA in MDCK cells. , 2002, Biochemical and biophysical research communications.
[167] Pauline M. Rudd,et al. Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9) , 2002, Critical reviews in biochemistry and molecular biology.
[168] Y. Iwakura,et al. IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[169] B. Sheu,et al. A novel role of metalloproteinase in cancer-mediated immunosuppression. , 2001, Cancer research.
[170] B. H. Shah,et al. GPCR-mediated transactivation of RTKs in the CNS: mechanisms and consequences , 2004, Trends in Neurosciences.
[171] Gillian Murphy,et al. Shedding of Syndecan-1 and -4 Ectodomains Is Regulated by Multiple Signaling Pathways and Mediated by a Timp-3–Sensitive Metalloproteinase , 2000, The Journal of cell biology.
[172] Michael Koval. Claudins—Key Pieces in the Tight Junction Puzzle , 2006, Cell communication & adhesion.
[173] T. Hoang‐Xuan,et al. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. , 2005, Biochimie.
[174] C. Blobel,et al. Remarkable roles of proteolysis on and beyond the cell surface. , 2000, Current opinion in cell biology.
[175] T. Morio,et al. Characterization of soluble CD40 ligand released from human activated platelets. , 2001, Journal of medical and dental sciences.
[176] T. Major,et al. Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Is Induced Upon Monocyte Differentiation and Is Expressed in Human Atheroma , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[177] P. Altevogt,et al. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins , 2001, The Journal of cell biology.
[178] M. Gassmann,et al. Viable c-Kit(W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis. , 2002, Immunity.
[179] M. Mareel,et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. , 2001, Journal of cell science.
[180] Christopher M. Overall,et al. Degradomics: Systems biology of the protease web. Pleiotropic roles of MMPs in cancer , 2006, Cancer and Metastasis Reviews.
[181] K. Matsumura,et al. Processing of beta-dystroglycan by matrix metalloproteinase disrupts the link between the extracellular matrix and cell membrane via the dystroglycan complex. , 2001, Human molecular genetics.
[182] E. Milgrom,et al. Cleavage and shedding of the TSH receptor. , 1997, European journal of endocrinology.
[183] O. Janssen,et al. Slowly getting a clue on CD95 ligand biology. , 2003, Biochemical pharmacology.
[184] M. Ryan,et al. Occludin: structure, function and regulation. , 2005, Advanced drug delivery reviews.
[185] D. Holtzman,et al. Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism , 2006, The Journal of Neuroscience.
[186] G. Gorodeski. Estrogen decrease in tight junctional resistance involves matrix-metalloproteinase-7-mediated remodeling of occludin. , 2007, Endocrinology.
[187] B. Castner,et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. , 1997, Nature.
[188] Hiroshi Sato,et al. Identification of the Second Membrane-type Matrix Metalloproteinase (MT-MMP-2) Gene from a Human Placenta cDNA Library , 1995, The Journal of Biological Chemistry.
[189] E. Appella,et al. A urokinase‐sensitive region of the human urokinase receptor is responsible for its chemotactic activity , 1997, The EMBO journal.
[190] G. Moţa,et al. Interaction of Human Immunoglobulin G with CD16 on Natural Killer Cells: Ligand Clearance, FcγRIIIA Turnover and Effects of Metalloproteinases on FcγRIIIA‐Mediated Binding, Signal Transduction and Killing ‡ , 2004, Scandinavian journal of immunology.
[191] Martin Braddock,et al. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention , 2004, Nature Reviews Drug Discovery.
[192] K. Irie,et al. Ectodomain shedding of nectin-1α by SF/HGF and TPA in MDCK cells , 2002 .
[193] K. Yudoh,et al. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. , 2001, The Journal of rheumatology.
[194] J. Pelley,et al. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Inflammatory Stimuli Up-Regulate Secretion of the Soluble GM-CSF Receptor in Human Monocytes: Evidence for Ectodomain Shedding of the Cell Surface GM-CSF Receptor α Subunit1 , 2002, The Journal of Immunology.
[195] R. Bast,et al. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor , 1994, Nature.
[196] Bahereh. The conversion , 1983, Craft Brew.
[197] Y. Kadono,et al. Negative Regulation of Osteoclastogenesis by Ectodomain Shedding of Receptor Activator of NF-κB Ligand* , 2006, Journal of Biological Chemistry.
[198] M. Ball,et al. Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. , 1994, Biochemical and biophysical research communications.
[199] M. Cuzner,et al. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system , 1999, Journal of Neuroimmunology.
[200] H. Yoshisue,et al. Effect of MMP/ADAM Inhibitors on Goblet Cell Hyperplasia in Cultured Human Bronchial Epithelial Cells , 2004, Bioscience, biotechnology, and biochemistry.
[201] Miki Hasegawa,et al. A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor , 1993, Nature.
[202] Norman Relkin,et al. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer’s disease , 2003, Neurochemistry International.
[203] S. Higashiyama. Metalloproteinase-mediated shedding of heparin-binding EGF-like growth factor and its pathophysiological roles. , 2004, Protein and peptide letters.
[204] Roy S Herbst,et al. Review of epidermal growth factor receptor biology. , 2004, International journal of radiation oncology, biology, physics.
[205] B. H. Shah,et al. Matrix metalloproteinase-dependent EGF receptor activation in hypertension and left ventricular hypertrophy , 2004, Trends in Endocrinology & Metabolism.
[206] M. Klagsbrun,et al. Matrix Metalloproteinase-3 Releases Active Heparin-binding EGF-like Growth Factor by Cleavage at a Specific Juxtamembrane Site* , 1997, The Journal of Biological Chemistry.
[207] R. Visse,et al. This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .
[208] J. Villeval,et al. Platelet activation induces metalloproteinase-dependent GP VI cleavage to down-regulate platelet reactivity to collagen. , 2005, Blood.
[209] I. Macdonald,et al. Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.
[210] A. Cress,et al. Integrin clipping: A novel adhesion switch? , 2004, Journal of cellular biochemistry.
[211] Y. Sasaguri,et al. Degradation of Interleukin 1β by Matrix Metalloproteinases* , 1996, The Journal of Biological Chemistry.
[212] J. Sandy,et al. Activation of the Proteolytic Activity of ADAMTS4 (Aggrecanase-1) by C-terminal Truncation* , 2002, The Journal of Biological Chemistry.
[213] Joseph D. Buxbaum,et al. Evidence That Tumor Necrosis Factor α Converting Enzyme Is Involved in Regulated α-Secretase Cleavage of the Alzheimer Amyloid Protein Precursor* , 1998, The Journal of Biological Chemistry.
[214] M. Fini,et al. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. , 2005, The American journal of pathology.
[215] J K Frederiksen,et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. , 2000, Science.
[216] M. Wewers. IL-1β: An endosomal exit , 2004 .
[217] T. Petrucci,et al. Synaptic remodeling induced by axotomy of superior cervical ganglion neurons: Involvement of metalloproteinase-2 , 2006, Journal of Physiology-Paris.
[218] S. Shumack,et al. Epidemiology and pathogenesis of scleroderma , 2003, The Australasian journal of dermatology.
[219] Munirah Ahmad,et al. Cleavage of amyloid-beta precursor protein (APP) by membrane-type matrix metalloproteinases. , 2006, Journal of biochemistry.
[220] K. Tanabe,et al. The role of Fas ligand and transforming growth factor β in tumor progression , 2004 .
[221] S. Yamasaki,et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. , 2000, Biochemical and biophysical research communications.
[222] K. Misono,et al. Proteolytic cleavage of atrial natriuretic factor receptor in bovine adrenal membranes by endogenous metalloendopeptidase. Effects on guanylate cyclase activity and ligand-binding specificity. , 1992, European journal of biochemistry.
[223] E. Levin,et al. Proximal Events in Signaling by Plasma Membrane Estrogen Receptors* , 2003, The Journal of Biological Chemistry.
[224] M. Polette,et al. Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. , 2001, The Journal of investigative dermatology.
[225] B. Fingleton,et al. Matrix metalloproteinases: biologic activity and clinical implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[226] F. Chen,et al. The Differentiation-dependent Desmosomal Cadherin Desmoglein 1 Is a Novel Caspase-3 Target That Regulates Apoptosis in Keratinocytes* , 2006, Journal of Biological Chemistry.
[227] P. Gottschall,et al. Increased Production of Matrix Metalloproteinases in Enriched Astrocyte and Mixed Hippocampal Cultures Treated with β‐Amyloid Peptides , 1996 .
[228] J. Elrod,et al. Extracellular matrix, junctional integrity and matrix metalloproteinase interactions in endothelial permeability regulation * , 2002, Journal of anatomy.
[229] C. Dinarello,et al. Proinflammatory cytokines. , 2000, Chest.
[230] R. Fridman,et al. MT1-MMP shedding involves an ADAM and is independent of its localization in lipid rafts. , 2006, Biochemical and biophysical research communications.
[231] R. Fridman,et al. MMP-2 colocalizes with caveolae on the surface of endothelial cells. , 2001, Experimental cell research.
[232] M. Hellwig,et al. Soluble Human Interleukin–4 Receptor Is Produced by Activated T Cells under the Control of Metalloproteinases , 1999, International Archives of Allergy and Immunology.
[233] R. Bast,et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. , 1994, Nature.
[234] P. Galle,et al. Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells , 2004, Oncogene.
[235] A. Elhabazi,et al. Biological Activity of Soluble CD100. I. The Extracellular Region of CD100 Is Released from the Surface of T Lymphocytes by Regulated Proteolysis1 , 2001, The Journal of Immunology.
[236] P. E. Van den Steen,et al. Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins , 2007, Journal of leukocyte biology.
[237] Z. Werb,et al. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. , 2005, The Journal of clinical investigation.
[238] I. Stamenkovic,et al. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. , 1999, Genes & development.
[239] Yunbo Shi,et al. Spatio‐temporal regulation and cleavage by matrix metalloproteinase stromelysin‐3 implicate a role for laminin receptor in intestinal remodeling during Xenopus laevis metamorphosis , 2005, Developmental dynamics : an official publication of the American Association of Anatomists.
[240] P. Libby,et al. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. , 1998, Journal of immunology.
[241] K. Ley,et al. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation , 2004, Nature Reviews Immunology.
[242] E. Ziff,et al. Membrane Localization of Membrane Type 5 Matrix Metalloproteinase by AMPA Receptor Binding Protein and Cleavage of Cadherins , 2006, The Journal of Neuroscience.
[243] B. Fingleton,et al. Matrix metalloproteinase-3-dependent generation of a macrophage chemoattractant in a model of herniated disc resorption. , 2000, The Journal of clinical investigation.
[244] Z. Werb,et al. How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.
[245] E. Milgrom,et al. Sequential Cleavage and Excision of a Segment of the Thyrotropin Receptor Ectodomain* , 1999, The Journal of Biological Chemistry.
[246] J. Ochieng,et al. Modulation of the biological functions of galectin-3 by matrix metalloproteinases. , 1998, Biochimica et biophysica acta.
[247] M. Campiglio,et al. The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1. , 2005, Endocrine-related cancer.
[248] Y. Okada,et al. Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases , 2003, Oncogene.
[249] M. Wewers. IL-1beta: an endosomal exit. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[250] R. Mayer,et al. Activation of Human Leukocytes Reduces Surface P-Selectin Glycoprotein Ligand-1 (PSGL-1, CD162) and Adhesion to P-Selectin In Vitro1 , 2000, The Journal of Immunology.
[251] M. Griese,et al. Surfactant protein D in human lung diseases , 2006, European journal of clinical investigation.
[252] K. Ley,et al. L‐selectin: mechanisms and physiological significance of ectodomain cleavage , 2005, Journal of cellular and molecular medicine.
[253] Dominic M. Walsh,et al. Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease , 2004, Neuron.
[254] Motoharu Seiki,et al. The cell surface: the stage for matrix metalloproteinase regulation of migration. , 2002, Current opinion in cell biology.
[255] A. Agarwal,et al. PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells , 2005, Cell.
[256] George Kollias,et al. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease , 1999, Annals of the rheumatic diseases.
[257] A. Mohsenin,et al. PECAM‐1 shedding during apoptosis generates a membrane‐anchored truncated molecule with unique signaling characteristics , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[258] T. Shofuda,et al. Membrane‐type matrix metalloproteinase‐1 and ‐3 activity in primate smooth muscle cells , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[259] H. Yamane,et al. HEMOSTASIS , THROMBOSIS , AND VASCULAR BIOLOGY Inflammatory Cytokines and Vascular Endothelial Growth Factor Stimulate the Release of Soluble Tie Receptor From Human Endothelial Cells Via Metalloprotease Activation , 1999 .
[260] S. Shapiro. Immunology: Mobilizing the army , 2003, Nature.
[261] R. Pope. Apoptosis as a therapeutic tool in rheumatoid arthritis , 2002, Nature Reviews Immunology.
[262] H. Kowarzyk. Structure and Function. , 1910, Nature.
[263] I. Stamenkovic,et al. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. , 2001, Cancer research.
[264] J. Gutkind,et al. MT1-MMP Controls Tumor-induced Angiogenesis through the Release of Semaphorin 4D* , 2007, Journal of Biological Chemistry.
[265] M. Tortorella,et al. Inhibition of ADAM-TS4 and ADAM-TS5 Prevents Aggrecan Degradation in Osteoarthritic Cartilage* , 2002, The Journal of Biological Chemistry.
[266] M. Cinelli,et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. , 2004, Arthritis and rheumatism.
[267] M. Bachem,et al. Oxidized Low-Density Lipoproteins Stimulate Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Release by Coronary Smooth Muscle Cells , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[268] J. Zwerina,et al. Mechanisms of Disease: the link between RANKL and arthritic bone disease , 2005, Nature Clinical Practice Rheumatology.
[269] G. Opdenakker,et al. The molecular basis of leukocytosis. , 1998, Immunology today.
[270] Y. Okada,et al. Constitutive and Induced CD44 Shedding by ADAM-Like Proteases and Membrane-Type 1 Matrix Metalloproteinase , 2004, Cancer Research.
[271] M. Piccart-Gebhart. Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn. , 2006, European journal of cancer.
[272] A. Strongin,et al. The Low Density Lipoprotein Receptor-related Protein LRP Is Regulated by Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) Proteolysis in Malignant Cells* , 2004, Journal of Biological Chemistry.
[273] Séverine Brulé,et al. The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. , 2006, Glycobiology.
[274] M. Klagsbrun,et al. Heparin-binding EGF-like growth factor. , 1997, Biochimica et biophysica acta.
[275] D. Metcalfe,et al. The biology of Kit in disease and the application of pharmacogenetics. , 2004, The Journal of allergy and clinical immunology.
[276] J. Arribas,et al. Protein ectodomain shedding. , 2002, Chemical reviews.
[277] Z. Werb,et al. The Serpin α1-Proteinase Inhibitor Is a Critical Substrate for Gelatinase B/MMP-9 In Vivo , 2000, Cell.
[278] K. Frei,et al. Occludin proteolysis and increased permeability in endothelial cells through tyrosine phosphatase inhibition. , 1999, Journal of cell science.
[279] Stephen J. Weiss,et al. Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[280] X. Puente,et al. Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors , 2004, Biological chemistry.
[281] A. Strongin,et al. Processing of Integrin αv Subunit by Membrane Type 1 Matrix Metalloproteinase Stimulates Migration of Breast Carcinoma Cells on Vitronectin and Enhances Tyrosine Phosphorylation of Focal Adhesion Kinase* , 2002, The Journal of Biological Chemistry.
[282] Hongtao Liu,et al. The role of apoptosis in rheumatoid arthritis. , 2003, Current opinion in pharmacology.
[283] Bo Liu,et al. Stem cell factor and c-kit are expressed by and may affect vascular SMCs through an autocrine pathway. , 2004, The Journal of surgical research.
[284] M. Kai,et al. Heparin-Binding EGF-Like Growth Factor Is a Promising Target for Ovarian Cancer Therapy , 2004, Cancer Research.
[285] C. Dijkstra,et al. The FASEB Journal • FJ Express Full-Length Article Diapedesis of , 2022 .
[286] Antal‐Szalmás,et al. Evaluation of CD14 in host defence , 2000, European journal of clinical investigation.
[287] L. Lum,et al. Biochemical and Pharmacological Criteria Define Two Shedding Activities for TRANCE/OPGL That Are Distinct from the Tumor Necrosis Factor α Convertase* , 2001, The Journal of Biological Chemistry.
[288] Y. Takada,et al. ADAM12/Syndecan-4 Signaling Promotes β1Integrin-dependent Cell Spreading through Protein Kinase Cα and RhoA* , 2002, The Journal of Biological Chemistry.
[289] G. Till,et al. A major role for neutrophils in experimental bullous pemphigoid. , 1997, The Journal of clinical investigation.
[290] H. Salih,et al. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. , 2006, Human immunology.
[291] A. Shinagawa,et al. Expression of the membrane-type 3 matrix metalloproteinase (MT3-MMP) in human brain tissues , 1998, Acta Neuropathologica.
[292] Jin-Moo Lee,et al. Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ* , 2006, Journal of Biological Chemistry.
[293] Michael J. Cullen,et al. Matrix Metalloproteinase-9 (MMP-9) Is Synthesized in Neurons of the Human Hippocampus and Is Capable of Degrading the Amyloid-β Peptide (1–40) , 1996, The Journal of Neuroscience.
[294] P. McGuire,et al. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood–retinal barrier , 2005, Laboratory Investigation.
[295] J. Powell,et al. Shear stress‐induced shedding of soluble intercellular adhesion molecule‐1 from saphenous vein endothelium , 2004, FEBS letters.
[296] I. Stamenkovic,et al. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.
[297] E. Kojro,et al. Ligand-induced Cleavage of the V2 Vasopressin Receptor by a Plasma Membrane Metalloproteinase (*) , 1995, The Journal of Biological Chemistry.
[298] H. Schaller,et al. Ectodomain shedding, translocation and synthesis of SorLA are stimulated by its ligand head activator. , 2000, Journal of cell science.
[299] Pedro Romero,et al. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity , 2002, Oncogene.
[300] R. Kemler,et al. Curbing the nuclear activities of beta-catenin. Control over Wnt target gene expression. , 2000, EMBO reports.
[301] Clifford J. Woolf,et al. Pain: Moving from Symptom Control toward Mechanism-Specific Pharmacologic Management , 2004, Annals of Internal Medicine.
[302] J. Walker,et al. Apoptosis a relevant therapeutic target in rheumatoid arthritis? , 2004, Rheumatology.
[303] R. Black,et al. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes , 1995, The Journal of experimental medicine.
[304] S. Bombardieri,et al. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP‐12‐dependent cleavage of the endothelial cell urokinase receptor , 2006, The Journal of pathology.
[305] A. Strongin,et al. Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-αv integrin regulates cross-talk between αvβ3 and α2β1 integrinsin breast carcinoma cells , 2003 .
[306] A. Mantovani,et al. Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition of mRNA expression, of the IL-1 type II receptor, with concomitant up-regulation of the type I receptor and induction of incompletely spliced transcripts. , 1999, Journal of immunology.
[307] P. Wallace,et al. Endotoxin induces rapid metalloproteinase‐mediated shedding followed by up‐regulation of the monocyte hemoglobin scavenger receptor CD163 , 2002, Journal of leukocyte biology.
[308] A. Rapraeger,et al. Syndecans in tumor cell adhesion and signaling , 2004, Reproductive biology and endocrinology : RB&E.
[309] J. Bonventre,et al. Recent advances in the pathophysiology of ischemic acute renal failure. , 2003, Journal of the American Society of Nephrology : JASN.
[310] Z. Werb,et al. Gelatinase B–deficient Mice Are Resistant to Experimental Bullous Pemphigoid , 1998, The Journal of experimental medicine.
[311] G. Bazzoni. Endothelial tight junctions: permeable barriers of the vessel wall , 2005, Thrombosis and Haemostasis.
[312] N. O. Solum,et al. Release of soluble CD40 ligand after platelet activation: studies on the solubilization phase. , 2004, Thrombosis research.
[313] M. Lambert,et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.
[314] S. Pflugfelder,et al. Advances in the diagnosis and management of keratoconjunctivitis sicca. , 1998, Current opinion in ophthalmology.
[315] R. Nagle,et al. Cleavage of β4 Integrin by Matrilysin , 1997 .
[316] E. Raines,et al. Emerging roles for ectodomain shedding in the regulation of inflammatory responses , 2006, Journal of leukocyte biology.
[317] S. Shapiro,et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. , 2000, The Journal of clinical investigation.
[318] D. Pinkel,et al. The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis , 1999, Cell.
[319] R. Koehler,et al. Dopamine Receptor Modulation of Hypoxic—Ischemic Neuronal Injury in Striatum of Newborn Piglets , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[320] Takashi Ishikawa,et al. Matrilysin (MMP-7) degrades VE-cadherin and accelerates accumulation of beta-catenin in the nucleus of human umbilical vein endothelial cells. , 2006, Oncology reports.
[321] M. Tessier-Lavigne,et al. Function of an axonal chemoattractant modulated by metalloprotease activity. , 2000, Science.
[322] F. Rentsch. Preretinal proliferation of glial cells after mechanical injury of the rabbit retina , 1973, Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie.
[323] D. Pei. Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. , 2005, Cancer cell.
[324] L. Kaczmarek,et al. Matrix metalloproteinases in the adult brain physiology: a link between c‐Fos, AP‐1 and remodeling of neuronal connections? , 2002, The EMBO journal.
[325] B. Toole,et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer. , 2001, The American journal of pathology.
[326] C. Masters,et al. Gelatinase A possesses a β‐secretase‐like activity in cleaving the amyloid protein precursor of Alzheimer's disease , 1995 .
[327] Luzhe Sun,et al. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase‐9 expression in a human xenograft model of prostate cancer , 2005, The Prostate.
[328] B. Fingleton,et al. Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. , 2001, Neoplasia.
[329] Séverine Brulé,et al. Regulated Shedding of Syndecan Ectodomains by Chemokines , 2006, TheScientificWorldJournal.
[330] John Calvin Reed. Mechanisms of apoptosis avoidance in cancer. , 1999, Current opinion in oncology.
[331] J. Buxbaum,et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. , 1998, The Journal of biological chemistry.
[332] A. Thathiah,et al. MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17. , 2004, The Biochemical journal.
[333] D. Collen. Ham-Wasserman lecture: role of the plasminogen system in fibrin-homeostasis and tissue remodeling. , 2001, Hematology. American Society of Hematology. Education Program.
[334] Zhi Liu. Immunopathology of bullous pemphigoid, an autoimmune and inflammatory skin blistering disease. , 2003, The Keio journal of medicine.
[335] María Yáñez-Mó,et al. Caveolae are a novel pathway for membrane-type 1 matrix metalloproteinase traffic in human endothelial cells. , 2003, Molecular biology of the cell.
[336] K. Bloom,et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. , 2003, The oncologist.
[337] R. Timpl,et al. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. , 1997, European journal of biochemistry.
[338] I. Stamenkovic,et al. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. , 2002, Genes & development.
[339] Constance E. Brinckerhoff,et al. Matrix metalloproteinases: a tail of a frog that became a prince , 2002, Nature Reviews Molecular Cell Biology.
[340] David A. Cheresh,et al. Role of integrins in cell invasion and migration , 2002, Nature Reviews Cancer.
[341] Tomoyuki Shirai,et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. , 2005, Cancer cell.
[342] T. Davis,et al. The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.
[343] R. Kemler,et al. Curbing the nuclear activities of β‐catenin , 2000 .
[344] T. Schöneberg,et al. The Fate of Desmosomal Proteins in Apoptotic Cells* , 2001, The Journal of Biological Chemistry.
[345] K. Tanabe,et al. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. , 2004, Cancer.
[346] J W Smith,et al. Substrate Hydrolysis by Matrix Metalloproteinase-9* , 2001, The Journal of Biological Chemistry.
[347] A. Shimizu,et al. A transmembrane chemokine, CXC chemokine ligand 16, expressed by lymph node fibroblastic reticular cells has the potential to regulate T cell migration and adhesion. , 2006, International immunology.
[348] R. Béliveau,et al. Ischemia injury alters endothelial cell properties of kidney cortex: stimulation of MMP-9. , 2005, Experimental cell research.
[349] M. Schwartz,et al. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. , 2006, Current topics in medicinal chemistry.
[350] M. Rio. From a unique cell to metastasis is a long way to go: clues to stromelysin-3 participation. , 2005, Biochimie.
[351] A. Strongin,et al. The Hemopexin-like C-terminal Domain of Membrane Type 1 Matrix Metalloproteinase Regulates Proteolysis of a Multifunctional Protein, gC1qR* , 2002, The Journal of Biological Chemistry.
[352] S. Tsukita,et al. Claudins in occluding junctions of humans and flies. , 2006, Trends in cell biology.
[353] U. Yazdani,et al. The semaphorins , 2006, Genome Biology.
[354] Z. Hochberg,et al. Shedding of growth hormone-binding protein is inhibited by hydroxamic acid-based protease inhibitors: proposed mechanism of activation of growth hormone-binding protein secretase. , 2001, The Journal of endocrinology.
[355] J. Baselga,et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. , 2001, Cancer research.
[356] M. Milla,et al. The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. , 2002, Biochemistry.
[357] S. Bohlson,et al. CD93 Is Rapidly Shed from the Surface of Human Myeloid Cells and the Soluble Form Is Detected in Human Plasma1 , 2005, The Journal of Immunology.
[358] R. Wynn,et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. , 1999, Science.
[359] G. Opdenakker,et al. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders , 1992, Journal of Neuroimmunology.
[360] J. Sandy,et al. ADAMTS4 (Aggrecanase-1) Activation on the Cell Surface Involves C-terminal Cleavage by Glycosylphosphatidyl Inositol-anchored Membrane Type 4-Matrix Metalloproteinase and Binding of the Activated Proteinase to Chondroitin Sulfate and Heparan Sulfate on Syndecan-1* , 2004, Journal of Biological Chemistry.
[361] Gerhard Christofori,et al. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer , 2004, Nature Reviews Cancer.
[362] B. H. Shah,et al. Matrix metalloproteinases in reproductive endocrinology , 2004, Trends in Endocrinology & Metabolism.
[363] P. Carmeliet,et al. uPAR: a versatile signalling orchestrator , 2002, Nature Reviews Molecular Cell Biology.
[364] S. Abraham,et al. Caveolae--Not Just Craters in the Cellular Landscape , 2001, Science.
[365] A. S. Appel,et al. Acute Renal Failure , 1960, Advances in Experimental Medicine and Biology.
[366] L. Lum,et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. , 1999, The Journal of biological chemistry.
[367] D. Cho,et al. Ligation of ICAM-1 molecules inhibits target cell-induced granule exocytosis of IL-12-activated natural killer cells. , 2000, Cellular immunology.
[368] M. Ploug,et al. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. , 1997, European journal of biochemistry.
[369] H. Mori,et al. CD44 directs membrane‐type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin‐like domain , 2002, The EMBO journal.
[370] E. Rovida,et al. Transmodulation of Cell Surface Regulatory Molecules via Ectodomain Shedding , 2002, Biological chemistry.
[371] L. Rassenti,et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. , 1999, The Journal of clinical investigation.
[372] E. Sturrock,et al. Modulation of juxtamembrane cleavage ("shedding") of angiotensin-converting enzyme by stalk glycosylation: evidence for an alternative shedding protease. , 1999, Biochemistry.
[373] E. Sturrock,et al. Phorbol ester-induced juxtamembrane cleavage of angiotensin-converting enzyme is not inhibited by a stalk containing intrachain disulfides. , 1998, Biochemistry.
[374] J. Nadel,et al. Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factor-alpha-converting enzyme in human airway epithelial (NCI-H292) cells. , 2004, American journal of physiology. Lung cellular and molecular physiology.
[375] D. Selkoe. Alzheimer Disease: Mechanistic Understanding Predicts Novel Therapies , 2004, Annals of Internal Medicine.
[376] G. Rosenberg,et al. Blood–brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation , 2006, Neurobiology of Disease.
[377] S. Nagata,et al. Downregulation of Fas ligand by shedding , 1998, Nature Medicine.
[378] J. Massagué,et al. Diverse Cell Surface Protein Ectodomains Are Shed by a System Sensitive to Metalloprotease Inhibitors (*) , 1996, The Journal of Biological Chemistry.
[379] K. Bryniarski,et al. Modulation of Macrophage Activity by Proteolytic Enzymes. Differential Regulation of IL-6 and Reactive Oxygen Intermediates (ROIs) Synthesis as a Possible Homeostatic Mechanism in the Control of Inflammation , 2003, Inflammation.
[380] L. Lum,et al. Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival* , 1999, Journal of Biological Chemistry.
[381] R. Nagle,et al. Cleavage of beta 4 integrin by matrilysin. , 1997, Experimental cell research.
[382] V. Magdolen,et al. Molecular and Functional Interdependence of the Urokinase-Type Plasminogen Activator System with Integrins , 2003, Biological chemistry.
[383] S. Chandler,et al. Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein. , 1996, Biochemical and biophysical research communications.
[384] T. Petrucci,et al. Axotomy of Sympathetic Neurons Activates the Metalloproteinase-2 Enzymatic Pathway , 2005, Journal of neuropathology and experimental neurology.
[385] N. Delaleu,et al. Interleukin-1 beta and interleukin-18: regulation and activity in local inflammation. , 2004, Periodontology 2000.
[386] W. Jiang,et al. Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[387] S. Théoleyre,et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.
[388] J. Massagué,et al. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites , 1994, The Journal of cell biology.
[389] J. Baselga,et al. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. , 1999, Cancer research.
[390] B. Fingleton,et al. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. , 2002, Archives of biochemistry and biophysics.
[391] B. H. Shah,et al. A central role of EGF receptor transactivation in angiotensin II -induced cardiac hypertrophy. , 2003, Trends in pharmacological sciences.
[392] F. Roufosse,et al. SYSTEMIC SCLEROSIS (SCLERODERMA) , 2007, Acta clinica Belgica.
[393] V. V. van Hinsbergh,et al. Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. , 2001, Blood.
[394] Motoharu Seiki,et al. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. , 2003, Cancer letters.
[395] N. Hooper,et al. Angiotensin-converting enzyme secretase is inhibited by zinc metalloprotease inhibitors and requires its substrate to be inserted in a lipid bilayer. , 1997, The Biochemical journal.
[396] P. Cameron,et al. Identification of a monocyte specific pre-interleukin 1 beta convertase activity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[397] K. Preissner,et al. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction , 1997, FEBS letters.
[398] A. Reichenbach,et al. P2Y receptor-mediated stimulation of Müller glial cell DNA synthesis: dependence on EGF and PDGF receptor transactivation. , 2003, Investigative ophthalmology & visual science.
[399] J. Baselga,et al. Metalloprotease-dependent Protransforming Growth Factor-α Ectodomain Shedding in the Absence of Tumor Necrosis Factor-α-converting Enzyme* , 2001, The Journal of Biological Chemistry.
[400] J. Kobarg,et al. A zinc metalloproteinase is responsible for the release of cd30 on human tumor cell lines , 1995, International journal of cancer.
[401] T. Gudermann,et al. Matrix Metalloproteinases 2 and 9 Mediate Epidermal Growth Factor Receptor Transactivation by Gonadotropin-releasing Hormone* , 2003, Journal of Biological Chemistry.
[402] G. Opdenakker,et al. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis , 2006, The Journal of experimental medicine.
[403] B. Imhof,et al. Integrin‐dependent pathologies , 2003, The Journal of pathology.
[404] P. Elwood,et al. The conversion of the human membrane-associated folate binding protein (folate receptor) to the soluble folate binding protein by a membrane-associated metalloprotease. , 1991, The Journal of biological chemistry.
[405] Jeffrey F. Thompson,et al. Matrix Metalloproteinase-Mediated Disruption of Tight Junction Proteins in Cerebral Vessels is Reversed by Synthetic Matrix Metalloproteinase Inhibitor in Focal Ischemia in Rat , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[406] F. Watt,et al. Role of integrins in regulating epidermal adhesion, growth and differentiation , 2002, The EMBO journal.
[407] E. Dı́az-Rodrı́guez,et al. Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling‐competent truncated forms , 1999, The European journal of neuroscience.
[408] E. Dejana,et al. Endothelial cadherins and tumor angiogenesis. , 2006, Experimental cell research.
[409] J. Marvaldi,et al. Role of endoproteolytic processing in the adhesive and signaling functions of alphavbeta5 integrin. , 2000, The Journal of biological chemistry.
[410] H. Mori,et al. CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase , 2005, Oncogene.
[411] B. H. Shah,et al. Neuropeptide-induced Transactivation of a Neuronal Epidermal Growth Factor Receptor Is Mediated by Metalloprotease-dependent Formation of Heparin-binding Epidermal Growth Factor* , 2004, Journal of Biological Chemistry.
[412] H. Galla,et al. Tyrosine phosphatase inhibition induces loss of blood–brain barrier integrity by matrix metalloproteinase-dependent and -independent pathways , 2004, Brain Research.
[413] J. Strominger,et al. Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes. Induction of cleavage of L-selectin via CD16. , 1994, Journal of immunology.
[414] J. Kirkwood,et al. Integrins and cancer. , 2007, Oncology.
[415] David C. Lee,et al. An essential role for ectodomain shedding in mammalian development. , 1998, Science.
[416] Hiroshi Sato,et al. Cleavage of apolipoprotein E by membrane-type matrix metalloproteinase-1 abrogates suppression of cell proliferation. , 2006, Journal of biochemistry.
[417] K. Campbell,et al. Dystroglycan: from biosynthesis to pathogenesis of human disease , 2006, Journal of Cell Science.
[418] F. Blasi,et al. Metalloproteases Cleave the Urokinase-Type Plasminogen Activator Receptor in the D1-D2 Linker Region and Expose Epitopes not Present in the intact Soluble Receptor , 2002, Thrombosis and Haemostasis.
[419] G. Opdenakker,et al. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis , 2003, The Lancet Neurology.
[420] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[421] J. Lissitzky,et al. Biogenesis of α6β4 integrin in a human colonic adenocarcinoma cell line , 1999 .
[422] A. Strongin,et al. Cellular Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) Cleaves C3b, an Essential Component of the Complement System* , 2004, Journal of Biological Chemistry.
[423] L. Lum,et al. Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. , 2001, The Journal of biological chemistry.
[424] Rita Casadio,et al. Transglutaminases: nature's biological glues. , 2002, The Biochemical journal.
[425] K. Endresen,et al. Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes. , 2006, Blood.
[426] M. Pepper. Role of the Matrix Metalloproteinase and Plasminogen Activator-Plasmin Systems in Angiogenesis , 2001, Arteriosclerosis, thrombosis, and vascular biology.